Curated Stack
Mitochondrial Stack: MOTS-c + Selank
mots-cselank
Editorial review by Pepticker Editorial· Pepticker editorial team
Published May 4, 2026
Protocol rationale
mots-c
MOTS-c
MOTS-c is a mitochondria-derived peptide (mitokine) that activates AMPK signalling to improve metabolic flexibility, insulin sensitivity, and exercise capacity in preclinical models. Published research uses 2–5 mg doses in rodent models; human research protocols often use 5 mg 2–3x/wk. The metabolic-longevity pathway (AMPK/mTOR axis) is distinct from GLP-1 agonist mechanisms.
5 mg/wk · 8 weeks
selank
Selank
Selank (heptapeptide TP-7) combines anxiolytic action (GABAergic modulation) with neuroprotective effects via BDNF upregulation in rodent models. Adds a cognitive/stress-resilience dimension to the metabolic-optimisation focus of MOTS-c. Typical research protocol: 250–500 mcg/day intranasal. The combination is not well-characterised in published literature; mechanistically complementary rather than synergistic.
0.25 mg/wk · 8 weeks
Interactive cost planner
Doses pre-filled from the editorial protocol. Adjust quantities and durations — costs and vendor recommendations update live.
1 — Select peptides (2–5)
MOTS-c
longevity
total mg
40.0
Selank
cognitive
total mg
2.0
+200 more — refine your search
Share this stack with pre-filled doses
2 — Cost analysis
Split purchaseCheapest
$118.43
Best vendor per peptide individually
Single vendor
$134.00
Best all-in-one: Atomik Labz
Split purchase saves $15.57 vs. single vendor — but requires 2 separate orders.
Dosing logistics
Total vials
2
mots-c: 1× 40mg
selank: 1× 5mg
BAC water vials
1
30 mL / 2 mL per recon
Syringes
56
7 inj/wk × longest protocol
3 — Purchase plan
4 — Vendor coverage
Expand to see which vendors carry which peptides in this stack.
Research purposes only. Pepticker is an editorial price comparator, not a clinical adviser. Prices are approximate and subject to change. Verify independently before any use. All vendors sell peptides for research only and not for human consumption.